List of Excipients in Branded Drug CYTOGAM

CYTOGAM Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 4, 2026

CYTOGAM is a U.S.-licensed human cytomegalovirus immune globulin intravenous product used for prophylaxis against CMV disease in transplant patients. Its formulation is deliberately simple: concentrated human IgG in an aqueous solution stabilized with glycine. The main commercial opportunities are supply reliability, formulation modernization, hospital-use efficiency, and geographic expansion rather than conventional small-molecule generic substitution.

CYTOGAM does not have an Orange Book patent listing because it is a biologic licensed under the Public Health Service Act. Its historical regulatory exclusivity has expired, but biological manufacturing complexity, plasma sourcing, clinical comparability, and limited market size remain meaningful barriers to competition.

What is CYTOGAM and how is it regulated?

CYTOGAM is cytomegalovirus immune globulin intravenous human, also identified as CMV-IGIV. It contains purified human immunoglobulin G derived from pooled human plasma with antibodies against cytomegalovirus.

Attribute	CYTOGAM profile
Active ingredient	Human cytomegalovirus immune globulin intravenous
Biological class	Plasma-derived polyclonal IgG
FDA pathway	Biologics license application
Administration	Intravenous infusion
Primary use	CMV prophylaxis in selected transplant recipients
Dosage strength	Approximately 50 mg/mL protein
Principal stabilizer	Glycine
Preservative	None
Dosage forms	Single-use intravenous vials
Patent database	Not listed in the FDA Orange Book
Competition pathway	351(k) biosimilar or 351(a) biologic, not an ANDA generic

The product label identifies CYTOGAM as a sterile solution containing human plasma protein, with at least 96% of the protein represented by IgG. Glycine is used as the stabilizer, and water for injection is the principal vehicle. The product does not contain a preservative.[1]

CMV prophylaxis is most relevant in solid-organ and hematopoietic-cell transplantation. Treatment protocols vary by transplant type, donor-recipient serostatus, antiviral strategy, and institutional guidelines. CYTOGAM is therefore purchased through specialized hospital, transplant-center, and specialty-distribution channels rather than through mass retail pharmacy networks.

What excipients are used in CYTOGAM?

CYTOGAM uses a low-excipient formulation designed to stabilize immunoglobulin during storage and intravenous administration.

Excipient or formulation component	Function	Commercial significance
Glycine	Protein stabilizer and tonicity contributor	Requires pharmaceutical-grade quality, low bioburden and endotoxin control
Water for injection	Solvent and infusion vehicle	Requires validated compendial water system
Human plasma proteins	Active biological matrix	Creates the principal manufacturing and safety burden
Container-closure system	Protects sterile protein solution	Important for extractables, leachables, adsorption and shipping integrity
No preservative	Reduces preservative-related infusion concerns	Requires single-use packaging and aseptic control

Glycine is the central excipient opportunity. It is widely used in immunoglobulin products because it can support protein stability without introducing the aggregation and tolerability issues associated with some alternative buffers. A glycine-based formulation also supports a relatively short and manageable excipient bill of materials.

The formulation strategy shifts risk away from excipient complexity and toward the biological product itself. Key quality attributes include aggregate formation, fragmentation, potency, antibody specificity, sterility, pyrogen control, viral safety, and protein concentration. A lower-cost excipient alone will not materially reduce total cost of goods if plasma procurement, fractionation, purification, viral clearance, and quality testing remain unchanged.

How does CYTOGAM’s excipient strategy compare with other immune globulin products?

CYTOGAM differs from many modern immune globulin products because its clinical value is linked to CMV-specific antibody content rather than only total IgG concentration. The formulation therefore cannot be evaluated solely on viscosity, infusion rate, or total protein recovery.

Product category	Typical formulation approach	Strategic implication
CMV-specific IVIG	Stabilized concentrated IgG with pathogen-specific antibody activity	Requires controlled donor serology and potency consistency
Standard IVIG	Broad-spectrum pooled IgG	Larger manufacturing scale and broader demand base
Subcutaneous immunoglobulin	Higher viscosity tolerance and frequent dosing	Often requires different concentration and delivery design
Recombinant antibody	Defined molecular composition	Avoids plasma-pool variability but may not reproduce polyclonal coverage
Monoclonal CMV antibody	Single-target antibody	Could offer dosing precision but requires clinical validation and a different regulatory strategy

CYTOGAM’s excipient platform is commercially conservative. It minimizes formulation novelty and preserves compatibility with established IVIG manufacturing. The tradeoff is that excipient innovation alone is unlikely to create a strong product distinction.

What formulation patents protect CYTOGAM?

No Orange Book-listed formulation patents protect CYTOGAM. The Orange Book covers approved drug products and patent certifications for applicable small-molecule products. It is not the principal patent register for biologics such as CYTOGAM.[2]

The relevant intellectual-property categories are:

1. Composition and formulation patents covering stabilized CMV immune globulin.
2. Manufacturing patents covering plasma pooling, fractionation, purification, viral inactivation or filtration.
3. Analytical patents covering CMV antibody potency and impurity measurement.
4. Use patents covering prophylaxis in defined transplant populations.
5. Packaging patents covering vial systems, storage, infusion or administration.
6. Trade secrets covering donor selection, plasma-pool composition, purification parameters and release specifications.

Publicly available FDA labeling does not establish that an active, enforceable formulation patent currently blocks CYTOGAM competition. A patent search would need to distinguish expired historical patents from live family members, terminal disclaimers, continuations, assignments and jurisdiction-specific rights. Patent term for an older plasma-derived biologic is unlikely to be the primary current barrier to entry.

When did CYTOGAM lose regulatory exclusivity?

CYTOGAM’s original biologic exclusivity period has expired. The product was approved before the modern 12-year reference-product exclusivity framework created by the Biologics Price Competition and Innovation Act. The BPCI Act provides 12 years of reference-product exclusivity for qualifying biological products, but that framework does not restore exclusivity to an older product whose approval predates the statute.[3]

CYTOGAM does not have small-molecule New Chemical Entity exclusivity, and an ANDA cannot be filed for it. A competitor would need to pursue either:

• A 351(k) biosimilar application, if the product can satisfy the biosimilar standard and reference-product requirements.
• A 351(a) full biologics license application for a separately developed biological product.
• A licensed product acquired or transferred through a commercial or regulatory transaction.

What is the Orange Book status of CYTOGAM?

CYTOGAM is not an Orange Book drug. The FDA Orange Book is primarily relevant to approved drugs under section 505 of the Federal Food, Drug, and Cosmetic Act. CYTOGAM is regulated as a licensed biologic under section 351 of the Public Health Service Act.[2]

The relevant FDA database for biological reference products and biosimilars is the Purple Book. A product’s absence from the Orange Book does not mean it has no intellectual-property protection. It means the applicable patent and exclusivity analysis is different.

For commercial diligence, the key questions are:

• Whether CYTOGAM is listed as a reference product in the Purple Book.
• Whether any biosimilar application has been submitted or approved.
• Whether the product’s current license holder has filed supplements involving formulation, manufacturing or indications.
• Whether private patent, licensing or settlement agreements restrict a competitor’s launch.

Which companies are challenging CYTOGAM?

There is no established U.S. ANDA challenger pathway for CYTOGAM. The most credible competitive threats would come from a plasma-derived CMV immune globulin, a biosimilar-like product, a standard IVIG regimen used off-label or under institutional protocol, or a different CMV prophylaxis strategy.

Potential competitive categories include:

Challenger	Competitive mechanism	Probability of direct substitution
Another CMV-specific immune globulin	Direct product competition	High if supply, labeling and reimbursement align
Standard IVIG	Broader IgG product used under selected protocols	Moderate, depending on clinical evidence
Antiviral prophylaxis	Pharmacologic prevention rather than passive immunization	High as a budget substitute in some transplant settings
CMV preemptive monitoring	Laboratory surveillance followed by treatment	Moderate to high in centers with established infrastructure
Biosimilar or follow-on CMV immune globulin	Lower-cost biological substitute	Uncertain; comparability and market size are barriers
Monoclonal CMV antibody	Defined antibody therapy	Low near-term substitution risk without outcome data

The main competitive pressure is not a Paragraph IV launch. It is treatment-protocol substitution. Transplant centers may compare CYTOGAM with antiviral prophylaxis, preemptive CMV PCR monitoring, or combinations of these approaches.

What generic entry risks exist for CYTOGAM?

A conventional generic launch is not available. A competitor must establish biological comparability and satisfy FDA requirements for a complex plasma-derived product.

The principal entry barriers are:

Plasma sourcing

CMV antibody titers vary across donors. A manufacturer must obtain sufficient CMV-seropositive plasma and maintain consistent plasma-pool characteristics. A shortage of suitable source plasma can constrain production even when demand is stable.

Potency consistency

Total IgG concentration is not enough. CMV-specific antibody activity, assay reproducibility and batch-to-batch consistency are central product attributes.

Viral and prion safety

Manufacturers must validate donor screening, pathogen testing, viral inactivation and removal, and other safety controls. These steps add cost and reduce the feasibility of small-scale production.

Process comparability

A follow-on product must address differences in fractionation, chromatography, filtration, stabilizer concentration, aggregation profile and antibody activity. The burden is higher than for a simple chemical formulation.

Limited addressable market

CMV prophylaxis is concentrated in transplant care. A narrow market reduces the return on a new biologic manufacturing program and makes supply-chain scale harder to achieve.

Hospital adoption

Even after approval, a challenger must obtain formulary acceptance, transplant-center confidence, reimbursement coverage and dependable delivery performance.

What commercial opportunities exist in CYTOGAM excipients?

The strongest opportunities are incremental and platform-oriented.

Glycine supply

A supplier can compete on high-purity, compendial-grade glycine with validated endotoxin, bioburden and elemental impurity controls. The opportunity is more attractive as a multiyear supply agreement covering several immunoglobulin products rather than CYTOGAM alone.

Alternate stabilizer development

An alternative amino-acid or buffer system could support improved storage stability, reduced aggregation or greater concentration. Such a change would require extensive comparability work and could trigger a prior-approval supplement or other FDA regulatory submission. It is a development opportunity, not a rapid commercial replacement.

Higher-concentration formulation

A more concentrated product could reduce infusion volume and improve hospital workflow. The formulation must control viscosity, protein aggregation, infusion tolerability and container-closure compatibility. Higher concentration may require new clinical and human-factors evidence.

Ready-to-use hospital presentation

Commercial improvements could include optimized vial sizes, dose-banding formats, clearer overfill control, barcode integration and packaging designed for transplant-pharmacy workflows. These changes may create value without changing the active biological ingredient.

Cold-chain and distribution services

Reliable refrigerated logistics, inventory buffering and regional distribution are commercially important because transplant centers cannot tolerate prolonged stockouts. A distributor with specialty-biologic capabilities may create more value than a low-cost excipient supplier.

Combination delivery systems

Subcutaneous or assisted-delivery versions could reduce infusion-center use, but this is a major development program. The product would need assessment of viscosity, dose volume, local tolerability, pharmacokinetics, immunogenicity and clinical effectiveness. It should not be treated as a simple excipient change.

How strong is CYTOGAM’s patent estate?

CYTOGAM’s current competitive position is better characterized as manufacturing-protected than patent-protected.

Protection category	Relative strength
Orange Book patent barrier	None
Regulatory exclusivity	Expired
Plasma sourcing	Strong practical barrier
Viral-safety validation	Strong technical barrier
CMV-specific potency control	Strong know-how barrier
Formulation complexity	Moderate
Manufacturing trade secrets	Potentially strong
Hospital and transplant-center relationships	Moderate commercial barrier
Biosimilar legal barrier	Product- and application-specific

The most defensible assets are likely to be know-how, validated processes, quality systems, source-plasma access and commercial relationships. Those assets can impede entry even when patent protection is limited.

What patent litigation and settlement issues affect CYTOGAM?

There is no widely recognized Orange Book Paragraph IV litigation framework for CYTOGAM. Any dispute would more likely involve:

• Patent infringement claims against a 351(a) or 351(k) applicant.
• Trade-secret allegations involving purification or potency testing.
• Contract disputes over plasma supply or distribution.
• Licensing rights tied to manufacturing technology.
• Regulatory challenges involving comparability, labeling or interchangeability.

A settlement could address launch timing, field-of-use restrictions, supply rights, royalty payments or manufacturing access. Such agreements may not be visible through the Orange Book because CYTOGAM is not listed there.

How does CYTOGAM compare with antiviral CMV prophylaxis?

CYTOGAM and antiviral prophylaxis address CMV risk through different mechanisms.

Factor	CYTOGAM	Antiviral prophylaxis
Mechanism	Passive CMV-specific antibody transfer	Suppression of viral replication
Product type	Plasma-derived biologic	Small-molecule or nucleotide analog drug
Supply risk	Dependent on plasma and fractionation	Dependent on chemical manufacturing
Administration	Intravenous infusion	Often oral, depending on regimen
IP pathway	Biologic patents and BLA history	Orange Book patents and exclusivity may apply
Main commercial issue	Specialized biologic supply and protocol use	Generic competition and resistance management
Substitution risk	Vulnerable to protocol changes	Vulnerable to safety, adherence and resistance concerns

CYTOGAM’s commercial outlook depends heavily on clinical guidelines, transplant-center practice and reimbursement. Excipient improvements can support convenience and supply economics, but they will not overcome a shift away from CMV immune globulin protocols.

What are the revenue and licensing opportunities?

CYTOGAM revenue is not generally disclosed as a standalone product metric by its commercial owner. The relevant revenue drivers are transplant procedure volume, CMV-risk population size, prophylaxis protocol adoption, dose intensity, reimbursement and supply continuity.

Commercial opportunities include:

1. Regional licensing for countries with limited access to CMV-specific immune globulin.
2. Contract manufacturing or fill-finish partnerships for plasma-derived products.
3. Glycine and sterile-water supply agreements.
4. Specialty distribution contracts with transplant centers.
5. Packaging and dose-optimization programs.
6. Co-development of concentrated or reduced-volume formulations.
7. Acquisition of regional rights from a holder seeking to rationalize its plasma portfolio.

Geographic expansion is constrained by local plasma regulations, donor eligibility rules, biologic registration requirements, cold-chain standards and transplant-market size. European markets may include different CMV immune globulin products and clinical practices, so U.S. CYTOGAM positioning cannot be transferred directly.

Key Takeaways

• CYTOGAM is a plasma-derived CMV-specific intravenous immunoglobulin, not an Orange Book-listed small-molecule drug.
• Its formulation uses glycine as the principal stabilizer and water for injection as the vehicle, with no preservative.
• Regulatory exclusivity has expired, but a conventional ANDA generic route is unavailable.
• The most significant entry barriers are plasma sourcing, CMV-specific potency, viral safety, process validation and hospital adoption.
• Direct patent protection is less important than manufacturing know-how and supply-chain control.
• The best excipient opportunities involve glycine supply, higher-concentration formulations, reduced infusion volume and improved hospital packaging.
• The largest competitive threat is protocol substitution by antiviral prophylaxis or preemptive CMV monitoring, not a conventional Paragraph IV generic launch.
• A biosimilar or follow-on CMV immune globulin would face a narrow market and substantial comparability requirements.

FAQs

Can CYTOGAM be substituted with standard IVIG?

Standard IVIG may be used in some clinical settings, but it is not automatically interchangeable with CYTOGAM. CYTOGAM is characterized by CMV-specific antibody activity, while standard IVIG has broader pooled IgG activity.

Does CYTOGAM contain sodium chloride?

The labeled formulation identifies glycine and water for injection as formulation components. Sodium chloride should not be assumed to be an excipient unless identified in the current product labeling or quality documentation.

Could a new glycine concentration create a separate CYTOGAM product?

A materially different glycine concentration could require formulation comparability, stability, manufacturing validation and FDA review. It would not automatically create a separate patent-protected product.

Is CYTOGAM eligible for automatic biosimilar interchangeability?

No automatic interchangeability should be assumed. FDA interchangeability is a separate regulatory determination from biosimilarity and depends on the product, application and supporting evidence.

What is the most valuable CYTOGAM commercial asset?

The most valuable assets are likely the validated plasma-derived manufacturing process, source-plasma access, CMV potency controls, regulatory history and transplant-center supply relationships rather than the excipient composition alone.

References

1. U.S. Food and Drug Administration. (2021). CYTOGAM: Cytomegalovirus immune globulin intravenous human prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

4. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Patient Protection and Affordable Care Act, Pub. L. No. 111-148.

5. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. FDA.